Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$38.43M$38.43M+14.3% vs Q1 2017 Net Income-$18.38M-$18.38MN/M vs Q1 2017 EPS Diluted-$0.46-$0.46N/M vs Q1 2017 Operating Income-$17,912,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
Free Cash Flowderived-$14,773,000N/M Margins · derivedOperating margin-46.6%−3.8 pt vs Q1 2017
Net margin-47.8%−14.8 pt vs Q1 2017
ended Mar 31, 2018 · filed May 1, 2018 · 31 d after period end